Moderate Evidence
Research Overview
Alixorexton Research for Cataplexy
An evidence-based overview of research examining Alixorexton in the context of cataplexy. This page synthesizes findings from peer-reviewed literature.
Research Summary
Orexin signaling normally prevents inappropriate muscle relaxation during wakefulness. By restoring OX2R activation, alixorexton reduced cataplexy episode frequency in Phase 2 trials. This addresses cataplexy through its root cause rather than downstream pathways.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Cataplexy
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Alixorexton may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.